Evidence-Based Clinical Practice Guidelines for Laser-Assisted Drug Delivery
- PMID: 35976634
- DOI: 10.1001/jamadermatol.2022.3234
Evidence-Based Clinical Practice Guidelines for Laser-Assisted Drug Delivery
Abstract
Importance: Laser-assisted drug delivery (LADD) is used for various medical and cosmetic applications. However, there is insufficient evidence-based guidance to assist clinicians performing LADD.
Objective: To develop recommendations for the safe and effective use of LADD.
Evidence review: A systematic literature review of Cochrane Central Register of Controlled Trials, Embase, and MEDLINE was conducted in December 2019 to identify publications reporting research on LADD. A multidisciplinary panel was convened to draft recommendations informed by the systematic review; they were refined through 2 rounds of Delphi survey, 2 consensus meetings, and iterative review by all panelists until unanimous consensus was achieved.
Findings: Of the 48 published studies of ablative fractional LADD that met inclusion criteria, 4 were cosmetic studies; 21, oncologic; and 23, medical (not cosmetic/oncologic), and 6 publications of nonablative fractional LADD were included at the request of the expert panel, producing a total of 54 studies. Thirty-four studies (63.0%) were deemed to have low risk of bias, 17 studies (31.5%) had moderate risk, and 3 (5.5%) had serious risk. The key findings that informed the guidelines developed by the expert panel were as follows: LADD is safe in adults and adolescents (≥12 years) with all Fitzpatrick skin types and in patients with immunosuppression; it is an effective treatment for actinic keratosis, cutaneous squamous cell carcinoma in situ, actinic cheilitis, hypertrophic scars, and keloids; it is useful for epidermal and dermal analgesia; drug delivery may be increased through the application of heat, pressure, or occlusion, or by using an aqueous drug solution; laser settings should be selected to ensure that channel diameter is greater than the delivered molecule; antibiotic prophylaxis is not recommended, except with impaired wound healing; antiviral prophylaxis is recommended when treating the face and genitalia; and antifungal prophylaxis is not recommended. The guideline's 15 recommendations address 5 areas of LADD use: (I) indications and contraindications; (II) parameters to report; (III) optimization of drug delivery; (IV) safety considerations; and (V) prophylaxis for bacterial, viral, and fungal infections.
Conclusions and relevance: This systematic review and Delphi consensus approach culminated in an evidence-based clinical practice guideline for safe and effective use of LADD in a variety of applications. Future research will further improve our understanding of this novel treatment technique.
Similar articles
-
Laser-Assisted Drug Delivery: A Systematic Review of Safety and Adverse Events.Pharmaceutics. 2022 Dec 7;14(12):2738. doi: 10.3390/pharmaceutics14122738. Pharmaceutics. 2022. PMID: 36559233 Free PMC article. Review.
-
Laser-Assisted Drug Delivery in the Treatment of Scars, Rhytids, and Melasma: A Comprehensive Review of the Literature.Aesthet Surg J. 2023 Feb 21;43(3):NP181-NP198. doi: 10.1093/asj/sjac286. Aesthet Surg J. 2023. PMID: 36325715 Review.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Laser-mediated Solutions: Breaking Barriers in Transdermal Drug Delivery.AAPS PharmSciTech. 2024 Jun 19;25(6):142. doi: 10.1208/s12249-024-02849-z. AAPS PharmSciTech. 2024. PMID: 38898170 Review.
-
Laser-assisted drug delivery: mode of action and use in daily clinical practice.J Dtsch Dermatol Ges. 2016 May;14(5):480-8. doi: 10.1111/ddg.12963. J Dtsch Dermatol Ges. 2016. PMID: 27119468 Review.
Cited by
-
Advances in laser therapies for the scar.Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 Feb 28;49(2):197-206. doi: 10.11817/j.issn.1672-7347.2024.230454. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024. PMID: 38755716 Free PMC article. Review. Chinese, English.
-
Practical management of hypertrophic scarring: the mayo clinic experience.Arch Dermatol Res. 2024 Jan 20;316(2):77. doi: 10.1007/s00403-023-02802-3. Arch Dermatol Res. 2024. PMID: 38244097
-
Laser-Assisted Drug Delivery: A Systematic Review of Safety and Adverse Events.Pharmaceutics. 2022 Dec 7;14(12):2738. doi: 10.3390/pharmaceutics14122738. Pharmaceutics. 2022. PMID: 36559233 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous